Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial.

Dyer RK, Weinstock MA, Cohen TS, Rizzo AE, Bingham SF; VATTC Trial Group.

J Invest Dermatol. 2012 Nov;132(11):2544-51. doi: 10.1038/jid.2012.227. Epub 2012 Jul 19.

2.

Oral prednisone use and risk of keratinocyte carcinoma in non-transplant population. The VATTC trial.

Baibergenova AT, Weinstock MA; VATTC Trial Group.

J Eur Acad Dermatol Venereol. 2012 Sep;26(9):1109-15. doi: 10.1111/j.1468-3083.2011.04226.x. Epub 2011 Sep 16.

PMID:
21923839
3.

Association between non-steroidal anti-inflammatory drugs and keratinocyte carcinomas of the skin among participants in the Veterans Affairs Topical Tretinoin Chemoprevention Trial.

Nunes AP, Lapane KL, Weinstock MA; VATTC Trial Group.

Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):922-9. doi: 10.1002/pds.2142. Epub 2011 Jun 18.

PMID:
21688346
4.

Tolerability of high-dose topical tretinoin: the Veterans Affairs Topical Tretinoin Chemoprevention Trial.

Geng A, Weinstock MA, Hall R, Eilers D, Naylor M, Kalivas J; VATTC Trial Group.

Br J Dermatol. 2009 Oct;161(4):918-24. doi: 10.1111/j.1365-2133.2009.09341.x. Epub 2009 Jun 11.

PMID:
19681859
5.

Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial.

Weinstock MA, Lee KC, Chren MM, Marcolivio K; VATTC Trial Group.

J Am Acad Dermatol. 2009 Aug;61(2):207-15. doi: 10.1016/j.jaad.2009.02.022. Epub 2009 Apr 26.

Supplemental Content

Loading ...
Support Center